IRE1α inhibitors as a promising therapeutic strategy in blood malignancies
W Wiese, N Siwecka, A Wawrzynkiewicz… - Cancers, 2022 - mdpi.com
Simple Summary Blood malignancies account for 6.9% of all cancer deaths. Inositol-
requiring enzyme 1 alpha (IRE1α), a part of the unfolded protein response (UPR), has been …
requiring enzyme 1 alpha (IRE1α), a part of the unfolded protein response (UPR), has been …
[HTML][HTML] Bortezomib-and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response
T Kubicki, K Bednarek… - American Journal of …, 2022 - ncbi.nlm.nih.gov
Proteasome inhibitors are among the most potent classes of drugs in multiple myeloma
treatment. One of the main challenges in myeloma therapy is acquired resistance to drugs …
treatment. One of the main challenges in myeloma therapy is acquired resistance to drugs …
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
M Pelon, P Krzeminski, Z Tracz-Gaszewska… - Frontiers in …, 2024 - frontiersin.org
Multiple myeloma is an incurable cancer that originates from antibody-producing plasma
cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin …
cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin …
Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG …
AD van Dijk, FW Hoff, Y Qiu, SE Hubner, RL Go… - Cancers, 2024 - mdpi.com
Simple Summary Bortezomib-containing chemotherapy did not improve the clinical outcome
in the AAML1031 study in terms of overall survival and event-free survival compared to …
in the AAML1031 study in terms of overall survival and event-free survival compared to …
[HTML][HTML] Autophagy-related mechanisms for treatment of multiple myeloma
Multiple myeloma (MM) is a type of hematological cancer that occurs when B cells become
malignant. Various drugs such as proteasome inhibitors, immunomodulators, and …
malignant. Various drugs such as proteasome inhibitors, immunomodulators, and …
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment
K Chroma, Z Skrott, J Gursky, J Bacovsky… - Cell Death & …, 2022 - nature.com
Despite several approved therapeutic modalities, multiple myeloma (MM) remains an
incurable blood malignancy and only a small fraction of patients achieves prolonged …
incurable blood malignancy and only a small fraction of patients achieves prolonged …
Research progress in proteasome inhibitor resistance to multiple myeloma.
J Wu, J Liu - Zhong nan da xue xue bao. Yi xue ban= Journal of …, 2021 - europepmc.org
多发性骨髓瘤 (multiple myeloma, MM) 是一种高度异质性恶性浆细胞疾病. 蛋白酶体抑制剂
(proteasome inhibitors, PIs) 是治疗 MM 的一线药物, 硼替佐米, 伊莎佐米和卡非佐米也广泛 …
(proteasome inhibitors, PIs) 是治疗 MM 的一线药物, 硼替佐米, 伊莎佐米和卡非佐米也广泛 …
[PDF][PDF] Endoplasmic reticulum stress and proteasome inhibitors in multiple myeloma: room for improvement
In the last 2 decades, we witnessed unprecedented progress in multiple myeloma research.
The median survival times doubled, and with the introduction of subsequent new …
The median survival times doubled, and with the introduction of subsequent new …
Treatment with HIV-protease inhibitor nelfinavir identifies membrane lipid composition and fluidity as a therapeutic target in advanced multiple myeloma
L Besse, A Besse, SC Stolze, A Sobh, EA Zaal… - Cancer research, 2021 - AACR
The HIV-protease inhibitor nelfinavir has shown broad anticancer activity in various
preclinical and clinical contexts. In patients with advanced, proteasome inhibitor (PI) …
preclinical and clinical contexts. In patients with advanced, proteasome inhibitor (PI) …
[HTML][HTML] 蛋白酶体抑制剂在多发性骨髓瘤中耐药的研究进展
吴姣， 刘竞 - Journal of Central South University Medical Sciences, 2021 - ncbi.nlm.nih.gov
多发性骨髓瘤(multiple myeloma， MM) 是一种高度异质性恶性浆细胞疾病。 蛋白酶体抑制剂(
proteasome inhibitors， PIs) 是治疗MM 的一线药物， 硼替佐米、 伊莎佐米和卡非佐米也广泛 …
proteasome inhibitors， PIs) 是治疗MM 的一线药物， 硼替佐米、 伊莎佐米和卡非佐米也广泛 …